audrey’s life science meeting picks for may-june 2011 · pdf file24/1/2016 ·...
TRANSCRIPT
1
Audrey’s Life Science Meeting Picks for Jan. 24, 2016 – August 2016
Complimentary Service of AudreysNetwork.com
Jan. 24, 2016
*************************************************************************
PMWC, Monday – Wednesday, Jan. 25-27, 2016
Event: Personalized Medicine World Conference
Date and Time: Monday, January 25, 2016 at 7:00 AM -Wednesday, January 27,
2016 at 5:00 PM (PST)
Location: Computer History Museum 1401 N Shoreline Blvd
Mountain View, CA 94043
See program details at http://2016sv.pmwcintl.com/all/
Price: $2,500 through Jan. 24, 2015
Register at https://www.eventbrite.com/e/pmwc-2016-sv-attendees-tickets-
14926919819
Event Description
The Personalized Medicine World Conference (PMWC) is the only fully integrated
conference to examine the advances and challenges of Personalized Medicine through
a practical lens. PMWC brings together the thought-leaders of business, government,
healthcare-delivery, research and technology into one information-rich, two-day
conference.
Tickets are not refundable!
These individuals all have played, and continue to play, tremendously critical roles in
shaping the human healthcare system, changing it from a general population approach to a
personalized and patient-centered care model. For this reason, their outstanding
contributions to medicine will be recognized by awarding them the Pioneer and Luminary
Awards at the upcoming Personalized Medicine World Conference 2016 Silicon Valley on
January 24-27.
The Luminary Awards will be presented to Dr. Roger Perlmutter for transforming two R&D
organizations and for the development of groundbreaking new therapies, and to Dr.
Esserman for her visionary approach towards breast cancer medicine.
The Pioneer Awards will go to Dr. Ralph Snyderman, referred to as the “father of
personalized medicine”, and to Dr. Irv Weissman, similarly referred to as the “father of
hematopoiesis”.
Join 1,100 peers in Silicon Valley on January 24 - 27, 2016
With more than 65 sessions, 130 speakers and three parallel tracks
Building on the groundwork for transformative patient-centered health care
at PMWC 2016 Silicon Valley
The adoption of personalized medicine is being driven by a multitude of advancements
across different disciplines that thrive on technological innovations. Next-generation
sequencing (NGS), computational power and mechanism-based biology are all
contributing to better disease diagnosis, prognosis and treatment. As such, more and
more individuals undergo NGS-based diagnostic testing, primarily in the area of
2
oncology. With these advancements and the President’s Precision Medicine Initiative it
is expected that in the near future we not only see larger populations getting tested,
but also having their DNA fully sequenced.
The value of NGS in this context is indisputable and as such we can observe a strong
interplay with the clinic — clinical adoption drives innovation even as NGS drives new
applications. As NGS adds to the identification and application of new biomarkers,
contributes to the understanding and characterization of the underlying biology of
human diseases, and aids in the identification and characterization of new drug
targets, a number of non-trivial challenges arise, such as increasing complexity in
clinical trial design and patient selection, and increased pressure to provide
justification of clear clinical value to both payers and patients.
The tenth Personalized Medicine World Conference (PMWC 2016), which will
take place from January 24 - 27 in Silicon Valley, will focus on these
developments in a collegial setting that fosters scientific exchange, networking and
partnering. The broad array of topics covered span biological, engineering and
computational advancements as well as research and commercial applications, and the
conference will touch upon issues such as data privacy and security, regulatory
updates and commercial opportunities. Lastly, a panel on "NGS & Clinical Interplay”
will provide multi-faceted perspectives from Helix’s new CEO, Peter Yu (ASCO), Cliff
Reid (Complete Genomics), Rick Klausner (Illumina), Allison Ballmer (Roche), Jonas
Korlach (PacBio) and others.
For more, visit us at: http://2016sv.pmwcintl.com
Follow us on Twitter to get more updates: @PMWCintl
LUMINARY AWARD RECIPIENTS
Laura Esserman, MD, MBA, is a recognized breast surgeon and breast oncology
specialist at the University of California, San Francisco leading a groundbreaking
national public-private collaboration combining personalized medicine with a novel
trial design, which has now become the new model for translational research. Dr.
Esserman is currently focusing on a 100,000 women breast cancer screening study
to determine whether a personalized approach to screening and treatment is safer
and more effective. Read Full Bio
Roger M. Perlmutter, MD, Ph.D, (President, Merck Research Laboratories and
previously Amgen) transformed two major R&D organizations and enabled the
expeditious development and subsequent approval of small molecule and biologic
medicines including the monoclonal antibody Denosumab (for the for the treatment
of osteoporosis) and the anti-PD1 therapy, Keytruda, to treat metastatic
melanoma.
PIONEER AWARD RECIPIENTS
Ralph Snyderman, MD (Chancellor Emeritus, Duke University and James B. Duke
Professor of Medicine in the Duke University School of Medicine), who has created
3
a transformative environment to improve our nation’s health over the last 40
years. During this time, he led the transition of the School of Medicine at Duke
University into a globally recognized leader of academic medicine and played a
leading role in the conception and development of Personalized Health Care, an
evolving model of national health care delivery. He was amongst the first to
envision and articulate the need to move the current focus of health care from the
treatment of disease-events to personalized, predictive, preventive, and
participatory care that is focused on the patient.
Irv Weissman, MD (Director of the Institute of Stem Cell Biology & Regenerative
Medicine at Stanford School of Medicine), contributed to the understanding of
hematopoiesis and moved the field of stem cell research forward to make successful
treatments a reality. Not only was he instrumental in isolating the first blood-
forming stem cells in mice and humans early on, he is also recognized for isolating
human Leukemia cancer stem cells. His work and discoveries on stem cell aging
contributed to the understanding of cancer stem cells and the immune system and
are pioneering achievements with far-reaching clinical applications.
*******************************************************************
QB3, Monday Midday, January 25, 2016
Topic: “The Problem Of Gastric Cancer In Emerging Economies”
Speaker: Alejandro Corvalan, MD, is Principal Investigator at the Advanced
Center for Chronic Diseases in Santiago, Chile.
Date and Time: Monday, January 25, noon to 1:00 pm
Location: QB3@953, 953 Indiana St., San Francisco
Fee: $10 for general admission
Register at http://www.eventbrite.com/e/qed-alejandro-corvalan-md-the-problem-
of-gastric-cancer-in-emerging-economies-tickets-
20021140771?mc_cid=59fb6e568d&mc_eid=cb4c38a44a
Topic Description
My laboratory is involved in translational cancer research at basic, clinical and
population levels. My research is primarily focused on cancer epigenetics with an
emphasis on the discovery and validation of tumor suppressor genes inactivated by
DNA methylation and/or microRNAs. These discoveries act as potential biomarkers
for the early diagnosis of cancer, monitoring treatment response and developing
new treatments. Through this research, we are developing a novel screening and
triage test for the early detection of gastric cancer based on cell free DNA in plasma
(NCT01774266) . I am also investigating the role of two p53-dependant tumor
suppresor genes, Reprimo (RPRM) and p73, in the pathogenesis of gastric cancer.
In addition to this, I have strong interest in cancer systems biology, specifically
exploring cancer heterogeneity through a data-mining approach by using existing
databases and open-source / in-house bioinformatic software.
Speaker Bio
Alejandro Corvalan, MD, is Principal Investigator at the Advanced Center for
Chronic Diseases in Santiago, Chile.
My laboratory is involved in translational cancer research at basic, clinical and
population levels. My research is primarily focused on cancer epigenetics with
an emphasis on the discovery and validation of tumor suppressor genes
4
inactivated by DNA methylation and/or microRNAs. These discoveries act as
potential biomarkers for the early diagnosis of cancer, monitoring treatment
response and developing new treatments. Through this research, we are
developing a novel screening and triage test for the early detection of gastric
cancer based on cell free DNA in plasma (NCT01774266) . I am also
investigating the role of two p53-dependant tumor suppresor genes, Reprimo
(RPRM) and p73, in the pathogenesis of gastric cancer. In addition to this, I
have strong interest in cancer systems biology, specifically exploring cancer
heterogeneity through a data-mining approach by using existing databases
and open-source / in-house bioinformatic softwares.
******************************************************************
Bio2Device Group, Tuesday Morning, Jan. 26, 2016
Topic: “Interstitial Pulmonary Disease”
Speaker: Sanjay K Agarwal, MD, FCCP, FAASM ,Comprehensive Sleep Center
Date and Time: Tuesday, Jan. 26, 2016, 8:30am
Location: Sunnyvale City Council Chambers, 456 West Olive Ave., Sunnyvale, CA
There is no fee or registration required for morning meetings.
Event Description
Dr. Agarwal will review different types of pulmonary diseases, including pathogenesis,
diagnostic modalities, and treatment considerations, with an emphasis on pulmonary fibrosis.
Speaker Bio
Dr. Agarwal is President and CEO of the Comprehensive Sleep Center and is affiliated with
Regional Medical Center, Good Samaritan Hospital, and O’Connor Hospital. He specializes in
Pulmonology, Critical Care Medicine, Internal Medicine, Interventional Pulmonology,
Pulmonary Critical Care Medicine, Pulmonary Diagnostics, Pulmonary Function Technology,
and Sleep Medicine. He is board certified in Critical Care Medicine, Pulmonary Disease, and
Sleep Medicine, and has a special interest in exotic pulmonary diseases: pulmonary fibrosis, lung
cancer and pulmonary hypertension. Dr. Agarwal attended Bangalore Medical College, Rajiv
Gandhi University of Health Sciences, completed his internship at Michael Reese Hospital, and
finished his residency at Michael Reese Hospital and his fellowship at SUNY Buffalo.
**********************************************************
JLABS, Tuesday Morning, Jan. 26, 2016
Event: Meet with…Canaan Partners
Speaker: Wende Hutton | General Partner, Canaan Partners
Date and Time: Tuesday, Jan. 26, 2016, 10:30 am – 1:00 pm
Location: Johnson & Johnson Innovation, JLABS, 329 Oyster Point Blvd - 3rd Floor,
South San Francisco, California
Fees:
Presentation & Lunch
$25 | General Public
$35 | General Public Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of
5
one-on-one meeting status. Registration to attend the presentation, Q&A, and lunch
will remain open until January 25th, 2016 (or sold out).
One-on-One Meeting
FREE | Application
FREE | Accepted Companies
Companies must have applied for a one-on-one meeting ahead of time. The one-on-
one application period ends on December 1st, 2015. Your application will be reviewed
and you will be notified of acceptance by January 5th, 2016 . Acceptance of a one-
on-one meeting is not guaranteed as all applications must be approved.
Register at http://www.eventbrite.com/e/meet-with-canaan-partners-tickets-
18496128418?aff=blast#s1
Event Description
Canaan Partners is a global venture capital firm that invests in entrepreneurs with visionary
ideas. With $4.2 billion under management and over 180 exits to date, Canaan has funded
some of the world's leading technology companies including LendingClub, Ebates,
PrimeSense, and Skybox Imaging as well as healthcare stars like Chimerix, Durata, Labrys
Biologics, and Civitas Therapeutics. Canaan recently announced Fund X, a $675 million fund
focused on early stage IT and healthcare startups. The fund's healthcare focus inclu
Wende Hutton, General Partner, will be in attendance on January 26th to provide an
overview presentation of Canaan's areas of interest and best practices when applying for
funding. Following the presentation, don't miss this opportunity to introduce yourself to
Wende during the networking lunch. And finally, for those companies who apply online and
are approved, one-on-one meetings with Wende will provide a forum to discuss your
company.
Speaker Bio
Wende Hutton | General Partner, Canaan Partners
Healthcare investor Wende Hutton brings 20 years of experience to identifying,
investing in and building companies that are changing the practice of medicine. She
has facilitated bringing over a dozen medical devices and drugs to market, and
currently sits on the boards of Butterfly Health, Chrono Therapeutics, Dermira, Glooko,
ReVision Optics, Theraclone Sciences and Transcend Medical. Prior investments include
BiPar Sciences (acquired by Sanofi-aventis), Chimerix (CMRX), and Labrys Biologics
(acquired by Teva Pharmaceutical). Wende was recognized among Fierce Biotech’s
2014 "Fierce 15" women in biotech and honored as one of The Most Influential Women
in Bay Area Business 2015 by The San Francisco Business Times. Wende joined Canaan
in 2004, and her life sciences track record includes seven IPOs and five acquisitions.
She began her venture career at Mayfield Fund in 1993, where she worked closely with
the founding teams of Heartstream (HPQ) and Northstar Neuroscience (NSTR). Earlier
in her career, Wende held senior operational management positions at GenPharm
International and Nellcor in business development and marketing. Wende holds an AB
in human biology from Stanford University and an MBA from Harvard Business School,
where she was a Baker Scholar. She is active with several community service groups
including serving on the board of FACE AIDS.
************************************************************
WIB, Complimentary Webinar, Tuesday Morning, Jan. 26,2016
6
Event: WIB-National Webinar: “NIH Small Business Programs: What Biomedical
Entrepreneurs Should Know”
Speakers: Stephanie Fertig and Kory Hallett, from the National Institutes of Health (NIH)
Date and Time: Tuesday, January 26, 2016, 11:00 am – 12:00 pm
Fees: Complimentary
Register at http://www.womeninbio.org/eventdetails.aspx?EventId=27564
Event Description
Stephanie Fertig and Kory Hallett, from the National Institutes of Health (NIH), will give an
overview of SBIR and STTR Small Business programs at the NIH. Their talk will include a
description of the program’s goals, tips on applying, and resources available to researchers
and small/startup businesses interested in translating their technologies into commercial
products. At the end of the presentation, the speakers will respond to questions from the
audience. If you want to find ways to expand your biomedical startup using NIH funding,
you won't want to miss this webinar! *************************************************************************************************************
Palo Alto AWIS, Wednesday Evening, Jan. 27, 2016
Topic: “Creating Memorable Presentations: Tips for Creating the Best Figures: Present Your
Data Clearly, Accurately, and Attractively
Speaker: Teresa Larsen, Ph.D.
Date and Time: Wednesday, January 27th, 2016, 7 - 9 PM
Location: PARC Auditorium, 3333 Coyote Hill Dr. Palo Alto, CA 94304
Cost: NonMembers: $10 Register at http://www.brownpapertickets.com/event/2488102?utm_source=AWIS+Palo+Alto+Program+Announcement+List+%28Complete%29&utm_campaign=9a716e0c97-Jan_2016_Teresa_Larsen1_10_2016&utm_medium=email&utm_term=0_d2fcf7050d-9a716e0c97-77505685
Topic Description
Do people's eyes glaze over when you present your data? Do you want to instead captivate
your audience? Applying creative presentation skills will allow you to convey your message
effectively and give your work the well-deserved visibility.
Speaker Bio
Dr. Larsen earned her doctoral degree in Biochemistry at UCLA. She has dedicated her
career to helping researchers explain their ideas in publications and presentations, so that
they can get funding to continue their work, commercialize their innovations, and conduct
outreach to explain their work to lay audiences. She has earned awards for computer
graphic animation and has many of her figures displayed as framed artwork.
*********************************************************
BioPharma Consortium, Wednesday Evening, Jan. 27, 2016
Event: “BioPharma Consortium 2016 New Year Mixer”
Come Celebrate the New Year in Style with the BioPharma Consortium!
Date and Time: January 27, 2016, 6:00-8:30 PM
Location: Porterhouse Restaurant
60 E. Third Ave.
San Mateo, CA
Pricing: $20, if pre-registered by noon January 20
$30 walk-in (cash only)
7
Register: http://www.biopharmaconsortium.com/events/2016/1/6/new-year-mixer-
january-27
Contact: http://www.biopharmaconsortium.com/contact/
Event Description
What's reigning in the talk of 2016?
A year ahead of VC growth....doubling down on drug pricing pressures....growing centers of
innovation.....globalization and regulatory implications.....more M&A?
In the coming months, keep an eye out for leading-edge programming at BPC.
Join us in the bar and lounge to catch the latest biotech beat over drinks & apps and expand
your network. Cash bar
*****************************************************************
BioScience Forum, Wednesday Evening, Jan. 27, 2016
Topic: “Development of Cyclic Dinucleotides as a Treatment and an Adjuvant for Cancer
Therapy”
Speaker: Thomas Dubensky, Ph.D., Chief Scientific Officer, Aduro Biotech
Date and Time: Wednesday, Jan. 27, 2016, 6:00 pm
6:00 PM - networking
7:00 PM - dinner
8:00 PM - presentation
Location: The Holiday Inn, 275 S Airport Blvd, South San Francisco, CA 94080
Price: $50 before 9PM, Monday, January 25th; $60 on-site, $40 full-time students pre-
registration, $50 full-time students on-site, $3 service fee will be added to the pre-
registration price
Register at https://www.cvent.com/events/bioscience-forum-thomas-dubensky-cso-at-
aduro-biotech/registration-e9612cd66136426ab812261aa2bc84f0.aspx
Topic Description
The production of type 1 interferon (IFN) by host cells in response to an invading pathogen
is mediated in part through the STING (Stimulator of IFN Genes) receptor. The STING
receptor is generally expressed at high levels in immune cells, including dendritic cells. Once
activated, it initiates multiple pathways, including interferons and chemokines, leading to
the development of an effective tumor antigen-specific T cell adaptive immune response.
Bacterial cyclic dinucleotides (CDNs) trigger IFN in a STING-dependent fashion. A compound
(ADU-S100) derived from a CDN-based small molecule platform at Aduro was synthesized
to test this approach as a therapeutic opportunity. In mouse tumor models, direct injection
of ADU-S100 into melanoma, colon and breast tumors profoundly inhibited tumor growth,
both locally and systemically, provided protection against tumor regrowth, and significantly
inhibited growth of distal tumors. Other studies demonstrate that vaccination with CDN-
adjuvanted recombinant protein induced STING-dependent, antigen-specific CD4 and CD8 T
cell responses, and correlated with protective immunity in a viral challenge model.
Dr. Dubensky will address the development of CDN-based targeting of the STING receptor
(in collaboration with Novartis) and the likely clinical approaches to best leverage this novel
mechanism of action. Other programs will also be discussed, including Aduro's LADD
platform of attenuated strains of Listeria that have been engineered to express tumor-
associated antigens and induce specific and targeted immune responses in both preclinical
and clinical studies.
8
Speaker Bio
Thomas W. Dubensky, Jr., Ph.D. has served as Chief Scientific Officer of Aduro Biotech since
2011. From 2009 to 2011, Dr. Dubensky served as CSO of Immune Design Corp., where he
was responsible for overseeing the development of immune therapies based on proprietary
molecularly defined adjuvants and dendritic cell targeting vaccine platforms. He was a co-
founder and CSO of Anza Therapeutics, Inc., which was spun out from Cerus Corporation in
2007, where he served as the VP of Research beginning in 2002. At Cerus and at Anza, he
helped to develop vaccine platforms based on attenuated strains of Listeria monocytogenes,
which serves as the technology basis for Aduro. Previously, Dr. Dubensky developed vaccine
platforms at Viagene Biotech, Inc., Chiron Corporation and Onyx Pharmaceuticals, Inc.
Dr. Dubensky has co-authored more than 60 scientific papers and is an inventor on more
than 25 issued U.S. patents. Dr. Dubensky received his B.A. in Bacteriology and
Immunology from the University of California, Berkeley; he earned his Ph.D. at the
University of Colorado Health Sciences Center; and he was a post-doctoral fellow at Harvard
Medical School in the Department of Pathology. ***********************************************************************************************
JLABS, Thursday Morning, Jan. 28, 2015
Event: Science 1st - Designing Nucleic Acid Medicines
Speakers:
Michael McManus | Associate Professor, UCSF School of Medicine read bio»
David Schaffer | Professor, Chemical and Biomolecular Engineering, Bioengineering,
Molecular and Cell Biology, UC Berkeley / Director, Berkeley Stem Cell Center read
bio»
Laura Sepp-Lorenzino | VP, Entrepreneur-in-Residence, Alnylam Pharmaceuticals read
bio»
[moderator] Beth Hill | Senior Director, Platform Innovation, Johnson & Johnson
Innovationread bio»
Date and Time: Thursday, Jan. 28, 2015, 8:30 – 11:45 am
Agenda:
8:30am | Registration Opens, Networking and Breakfast
9:25am | Introduction
9:30am | Presentation and Q&A
11:15am | Panel Discussion and Q&A
11:45am | Close
Location: UCSF - Byers Auditorium, Genentech Hall,600 16th St , San Francisco, CA
94158
Fees:
$25 General Public - pre-registration will remain open until 5:00pm on Jan 27th
$15 Student/Academic - pre-registration will remain open until 5:00pm on Jan 27th
$35 At the door - at the door registration will open at 8:30pm on Jan 28th
Details and registration at http://www.eventbrite.com/e/science-1st-designing-
nucleic-acid-medicines-tickets-18375547758?aff=weekly
About the Science First series:
The Science First series, sponsored by Johnson & Johnson Innovation, JLABS, brings
together top experts to explore pressing topics in their scientific field. It is a chance
for local scientists, researchers, and entrepreneurs to present and dialogue on new
discoveries, advancing techniques, and other cutting-edge science themes.
Speakers' Biographies:
9
Michael McManus, Ph.D. | Associate Professor, UCSF School of Medicine
Dr. McManus obtained his Ph.D. from the University of Alabama in Birmingham,
where he studied RNA editing in the laboratory of Stephen L. Hajduk. In 2000, he did
his postdoctoral training as a Cancer Research Institute fellow, in the laboratory of
Nobel Laureate Phillip A. Sharp at the Massachusetts Institute of Technology (MIT),
studying the role of RNA-interference pathways in mammals. He is appointed as an
Associate Professor at the University of California San Francisco, in the Department
of Microbiology and Immunology. He is the founder and Director of the W.M. Keck
Center for Noncoding RNAs and also oversees the Sandler Lentiviral RNAi Core at
UCSF. He has a long-standing interest in post-transcriptional gene regulation and the
role of small RNAs in gene expression.
^ Back to Speakers' list ^
David Schaffer, Ph.D. | Professor, Chemical and Biomolecular Engineering,
Bioengineering, Molecular and Cell Biology, University of California at Berkeley /
Director, Berkeley Stem Cell Center
David Schaffer is a Professor of Chemical and Biomolecular Engineering,
Bioengineering, and Neuroscience at University of California, Berkeley, where he also
serves as the Director of the Berkeley Stem Cell Center. He graduated from Stanford
University with a B.S. degree in Chemical Engineering, and from Massachusetts
Institute of Technology with a Ph.D. in Chemical Engineering. He did a postdoctoral
fellowship in the laboratory of Fred Gage at the Salk Institute for Biological Studies in
La Jolla, CA. At UC Berkeley, Dr. Schaffer applies engineering principles to enhance
stem cell and gene therapy approaches for neuroregeneration, work that includes
novel approaches for molecular engineering and evolution of new viral vectors as well
as new technologies to investigate and control stem cell fate decisions.
Connect with David:
^ Back to Speakers' list ^
Laura Sepp-Lorenzino, Ph.D. | VP, Entrepreneur-in-Residence, Alnylam
Pharmaceuticals
Laura Sepp-Lorenzino, Ph.D. is Entrepreneur-in-Residence at Alnylam
Pharmaceuticals, a leading Cambridge MA biopharmaceutical company developing
novel therapeutics based on RNA interference. Dr. Sepp-Lorenzino joined Alnylam in
2014, and is leading the Hepatic Infectious Disease Strategic Therapeutic Area.
Before joining Alnylam, Dr. Sepp-Lorenzino spent 14 years at Merck & Co., having
most recently served as Executive Director and Department Head, RNA Therapeutics
Discovery Biology. In this role, she was responsible for identification and optimization
of siRNAs and delivery vehicles, advancement of pre-clinical candidates, and
development of an siRNA-conjugate platform to expand the repertoire of tissues
accessible to in vivo siRNA delivery. Prior to RNAi, Laura worked in oncology drug
discovery and development, having led the Cancer Research Department at Merck
West Point, and having been an Assistant Lab Member at Memorial Sloan-Kettering
Cancer Center. Laura received her Professional Degree in Biochemistry from the
University of Buenos Aires, and her M.S. and Ph.D. in Biochemistry from New York
University.
Connect with Laura:
^ Back to Speakers' list ^
10
[moderator] Beth Hill, Ph.D. | Senior Director, Platform Innovation, Johnson &
Johnson Innovation
Beth Hill is Senior Director of Platform Innovation at Johnson & Johnson Innovation,
California. She is an experienced pharmaceutical innovator with many years of
strategic and operational leadership in creating and applying technologies that
overcome technical and business barriers. Formerly with Janssen R&D, Beth led
global cross-disciplinary functions working from late discovery through development
and commercialization with a focus on drug delivery and drug+device combination
products. Beth has also led R&D teams to develop therapeutics for cancer and
autoimmune disease. At Systemix /Novartis she held functional and project
leadership roles in stem, somatic cell and gene therapies. She began her industrial
career developing antibody-based diagnostics at Syva Co. Beth earned her BA in
Medical Technology at Augustana College, her PhD in Microbiology at Columbia
University, and completed her post-doctoral studies in the Stanford Department of
Structural Biology.
Connect with Beth: *************************************************************************************************
QB3 Workshop, Starts Thursday, Jan. 28- March 21, 2016
Event: “Get Your Startup Funded. Take The Qb3 Sbir Workshop, Offered At Uc Berkeley And
Ucsf”
UCSF Nine sessions
Dates: Starts Thurs. Jan. 28, ends Thurs. Mar. 31
Location: Byers Hall, UCSF Mission Bay
hare QB3 NIH/NSF SBIR Workshop Spring 2016 at UCSF
Event Details
Register now for the QB3 NIH/NSF SBIR Workshop
UCSF Mission Bay
UCSF SBIR course description
Five two-and-a-half hour SBIR classes, with two additional one-hour sessions on Phase 2
submissions and resubmissions, and two additional one-hour sessions on NSF submissions.
Starting Thursday, January 28th and concluding Thursday, March 31st.
There are a limited number of seats, so please sign up as soon as possible by registering
here on Eventbrite.
This five-session workshop will take you through all the steps necessary to successfully file
a well-written SBIR/STTR grant application for the April 5 NIH deadline and the June 8 NSF
deadline. This course will focus on crafting a well-structured research plan, getting
persuasive letters of support, crafting an efficient budget, and helping you anticipate
reviewers’ comments. We will help you speed through the application instructions, saving
you hours of time. The course culminates in a submission clinic that will ensure your
application is correctly filed.
One or more team members from the company should be prepared to attend every session.
Remember to bring your laptop; these will be working sessions.
Course includes
• Five 2.5-hour working sessions
• One 1-hour resubmission working session
• One 1-hour Phase 2 working session
• Two 1-hour NSF working sessions
• Pre-submission review of specific aims by our course instructors
11
Topics include
• Understanding the requirements of an SBIR
• Preparing to apply for an SBIR (company formation, registration at all required
websites, identifying the best PI)
• Assembling all the necessary parts of the application (letters of support, sub-contract
quotes and letters, facilities to execute the grant, and research plan)
• Composing a competitive research plan
• Understanding and assembling a budget and justification
• Documentation required to use human samples, vertebrate animals, select agents,
resources
• Composing competitive innovation and significance sections as well as specific aims
• Searching for program announcements and finding opportunities
• Assembling and filing (completing the 424 correctly and filing on time)
Schedule
Dates Time Location Agenda
1/28 (Thurs) 1:00-3:30 pm BH-212 SBIR session 1
2/11 (Thurs) 1:00-4:30 pm BH-212 SBIR session 2 + NSF session 1
2/25 (Thurs) 1:00-4:30 pm BH-212 SBIR session 3 + NSF session 2
3/17 (Thurs) 1:00-4:30 pm BH-212 SBIR session 4 + Phase 2 session
3/31 (Thurs) 1:00-4:30 pm BH-212 SBIR session 5 + SBIR resubmission session
Standard rate for the entire 14-hour workshop: $750 per company
Discounted rate for UC affiliates, QB3 Startup in a Box Members, and QB3 Accelerator
Members: $250 for entire course per company
Startup in a box membership fee for new members includes this workshop. If you fall under
this category, you may register for free (ask Crystal Nyitray for the code).
A light snack and coffee is included for all sessions.
Acceptance into a future course is guaranteed with a waived fee if the company’s application
is unsuccessful.
Have questions about QB3 NIH/NSF SBIR Workshop Spring 2016 at UCSF? Contact QB3
Details and registration at https://www.eventbrite.com/e/qb3-nihnsf-sbir-workshop-spring-
2016-at-ucsf-tickets-19712585875?mc_eid=cb4c38a44a&mc_cid=b99e62a819
UC Berkeley: Four sessions
Dates: Starts Wed. Jan. 20, ends Wed. Mar. 16
Location: Stanley Hall, UC Berkeley
QB3 NIH SBIR Workshop Spring 2016 at Berkeley
QB3
Wednesday, January 20, 2016 at 1:00 PM - Wednesday, March 16, 2016 at 4:00 PM (PST)
Berkeley, CA
Register now for the QB3 NIH/NSF SBIR Workshop at UC Berkeley
Four two-and-a-half hour SBIR classes, starting Wednesday, January 20th and concluding
Wednesday, March 16th.
There are a limited number of seats, so please sign up as soon as possible by registering
here on Eventbrite.
12
This four-session workshop will take you through all the steps necessary to successfully file
a well-written SBIR/STTR grant application for the April 5 NIH SBIR deadline. This course
will focus on crafting a well-structured research plan, getting persuasive letters of support,
crafting an efficient budget, and helping you anticipate reviewers’ comments. We will help
you speed through the application instructions, saving you hours of time. The course
culminates in a submission clinic that will ensure your application is correctly filed.
One or more team members from the company should be prepared to attend every session.
Remember to bring your laptop; these will be working sessions.
Topics include
• Understanding the requirements of an SBIR
• Preparing to apply for an SBIR (company formation, registration at all required
websites, identifying the best PI)
• Assembling all the necessary parts of the application (letters of support, sub-contract
quotes and letters, facilities to execute the grant, and research plan)
• Composing a competitive research plan
• Understanding and assembling a budget and justification
• Documentation required to use human samples, vertebrate animals, select agents,
resources
• Composing competitive innovation and significance sections as well as specific aims
• Searching for program announcements and finding opportunities
• Assembling and filing (completing the 424 correctly and filing on time)
Schedule
Dates Time Location
1/20 (Weds) 1:30-4:00 pm Stanley Hall 177
2/10 (Weds) 1:30-4:00 pm Stanley Hall 177
3/2 (Weds) 1:30-4:00 pm TBD
3/16 (Weds) 1:30-4:00 pm TBD
Instructors:
Gabrielle G. Leblanc, PhD, Bioscience Consulting
Crystal Nyitray, PhD, Entrepreneurship Program Manager
Standard rate for the entire 14-hour workshop: $750 per company
Discounted rate for UC affiliates, QB3 Startup in a Box Members, and QB3 Accelerator
Members: $250 for entire course per company
The QB3 Startup in a Box membership fee for new members includes this workshop. If you
fall under this category, you may register for free (ask Crystal Nyitray for the code).
A light snack and coffee is included for all sessions.
Acceptance into a future course is guaranteed with a waived fee if the company’s application
is unsuccessful.
DetD
Course Description
For entrepreneurs looking for non-dilutive federal funding to get life science startups off the
ground. We walk you through your grant application to ensure you complete everything
properly and submit by the April 5 NIH deadline. Entrepreneurs applying through the QB3
workshop are 3x more likely than the nationwide average to get funded!
See the individual registration pages for class dates and locations. The UCSF thread includes
a special focus on NSF SBIRs, Phase 2 awards, and resubmission.
13
Find details and registration at https://www.eventbrite.com/e/qb3-nih-sbir-workshop-
spring-2016-at-berkeley-tickets-19712795502?mc_cid=b99e62a819&mc_eid=cb4c38a44a
************************************************************************
JLABS, Tuesday Morning, Feb. 2, 2016
Topic:” Between Two Benches: From corporate to entrepreneur and back…
Speakers:
Uri Lopatin | Chief Medical Officer & Vice President of R&D, Assembly Biosciences
[interviewer] Jeff Calcagno | New Ventures Johnson & Johnson Innovation
Date and Time: Tuesday, Feb. 2, 2015, 11:30 am
11:30am | Registration Opens, Lunch and Networking
12:00pm | Presentation, Interview and Q&A
1:00pm | Program Close
Location: Johnson & Johnson Innovation, JLABS, 329 Oyster Point Blvd - 3rd Floor,
South San Francisco, California
Fees:
$25 | General Public
$15 | Academic/Student Rate
$35 | At the door
Details and registration at http://www.eventbrite.com/e/between-two-benches-from-
corporate-to-entrepreneur-and-back-tickets-19250834765?aff=weekly
Event Description
Healthcare entrepreneurs start companies to create solutions that ultimately benefit
patients; but this is a long journey, with few road signs along the way. Join us on
February 2 to hear insights and lessons learned from a successful founder and CMO
of one of the first JLABS @ 953 "graduates", Assembly Biosciences.
Uri Lopatin, Founder and Chief Medical Officer at Assembly Biosciences (ASMB) will
be interviewed by Jeff Calcagno of Johnson & Johnson Innovation. The conversation
will focus on the making of a healthcare entrepreneur, how he navigated his way
from academia to big biotech to start up, and how he and his teammates-with help
from Johnson & Johnson Innovation-led Assembly Biosciences from seed stage to
public company in less than two years. The pair will be look at the highlights of Uri's
journey, including early mistakes and successes, surprises, lessons learned from
working with investors and with Johnson & Johnson Innovation, and more.
Don't miss the opportunity to learn from this lively and candid discussion between
two individuals who are making a difference in the biotech space.
The Inspiring Leader Series provides an intimate forum for biotech veterans and
experts to share their career successes and challenges. Each accomplished speaker
shares lessons learned over the course of his or her professional adventure. The
audience is comprised largely of entrepreneurs getting ready to embark on his or her
own company-building journey. The series is an interactive and inspiring experience.
Speaker Bios
Uri Lopatin, M.D. | Chief Medical Officer & Vice President of R&D, Assembly
Biosciences
Dr. Lopatin is a co-founder and the Chief Medical officer and VP R&D for Assembly
Pharmaceuticals, Inc. Prior to Assembly, he was a Senior Director for Clinical and
Translational Research-Liver Disease at Gilead Sciences, a Translational Medical
14
Leader at Roche, and an Associate Director at Schering Plough. He has designed and
coordinated pre-clinical and clinical collaborations, as well as phase I through IV
clinical studies of multiple new molecular entities. Dr. Lopatin has published
extensively, especially on hepatitis B and immunology and is an author of multiple
patents in the field of treatment and diagnosis for viral hepatitis. Dr. Lopatin received
his infectious disease Board certification following fellowship training in ID at the
NIH, and internal medicine board certification following completion of residency at
NYU. He received his MD in 2000 from University of Medicine and Dentistry-New
Jersey Medical School, where he was the recipient of the Stanley S Bergen medal of
excellence. He holds a BA in biology from Cornell University, where he graduated cum
laude with distinction in all subjects.
Connect with Uri:
Jeff Calcagno, M.D. | New Ventures, Johnson & Johnson Innovation
Jeff is a senior operating and business development executive focused on healthcare
innovation. He is based in Johnson & Johnson's California Innovation Center, which
he helped to establish. He is a member of the New Ventures team, which is
responsible for identifying promising new technologies for Johnson & Johnson (J&J),
the world's largest healthcare company, and for structuring optimal business
relationships. Jeff's career has spanned healthcare and business for over two decades
and has included roles as a management consulting at McKinsey & Company and as a
research analyst at JP Morgan H&Q. A former entrepreneur who has raised over
$50MM in venture money, he ran corporate development for WIDCOMM, a technology
company acquired by Broadcom, and served as CFO & CBO for Vela Pharmaceuticals,
a venture-backed drug development company. From 2006 to 2010 he was a Principal
& Kauffman Fellow at Scale Venture Partners, a venture fund with over $1B under
management. Jeff graduated Phi Beta Kappa in Biology from Harvard College and
earned an M.D. from Harvard Medical School. He completed his psychiatry residency
at UCLA's Neuropsychiatric Institute and was chosen as program chief resident.
Afterwards, he was awarded and completed a clinical neuropharmacology fellowship
focusing on the care of treatment-refractory patients. A former Rotary International
Ambassadorial Scholar, Jeff is conversational in six languages.
***********************************************************************************************
Bio2Device Group, Tuesday Morning, Feb. 2, 2016
Topic: “Intellectual Property Protection and Strategy for the New Venture”
Date and Time: Tuesday, Feb. 2, 2016, 8:30am
Location: Sunnyvale City Council Chambers, 456 West Olive Ave., Sunnyvale, CA
George Willman, MBA, JD and Nina Borders, JD Partner and Associate, ReedSmith LLP
There is no fee or registration required for morning meetings.
Event Description
Life science ventures view intellectual property rights as competitive advantages and key
assets. What are intellectual property rights, and how do they provide an advantage to the
new venture? What is a patent, a copyright, a trademark? What intellectual property
strategies should a new venture employ? How does the new venture handle intellectual
property upon founding and during growth to build a strong portfolio? Attend this session to
gain a valuable understanding of how these most important legal concepts are applied in the
business context, and how you may avoid many of the common intellectual property pitfalls
that trouble new ventures.
Speaker Bios
15
George Willman practices in the areas of technology transactions, patents, and intellectual
property counseling. Representative transactions include licensing, development, service,
distribution, manufacturing, electronic commerce, FinTech and corporate partnering
agreements. He counsels on intellectual property issues raised by merger and acquisition
transactions and initial public offerings. George is a registered patent attorney.
Prior to his legal career, George worked as a software and telecommunications engineer for
ROLM, IBM, and Siemens in Silicon Valley and Munich, Germany.
George serves as a mentor at the Lester Center for Entrepreneurship and Innovation at the
University of California, Berkeley. In addition to English, he speaks German and holds a
Certificat de Français Scientifique et Technique.
Nina Borders is an associate in the firm's Intellectual Property Litigation Group, focusing on
patent and trademark prosecution and litigation. Nina has represented clients in a wide
range of patent, trademark, and trade secret matters in food, chemical, pharmaceutical,
biochemical, and mechanical technologies. Nina has significant experience with trademark
registration and counseling. She also has experience with reexamination proceedings before
the Patent Office and oversees domestic and international trademark and patent portfolios
for clients in a variety of industries. Nina is a registered patent attorney, and has a broad
technical background, with nearly 10 years of experience in the food and pharmaceutical
industries prior to beginning her legal career with Reed Smith.
***************************************************************
BMES Industry Networking Group: San Francisco/Bay Area, Tuesday Evening, Feb.
2, 2016
Topic: “The Future of BioMedicine: Where Can Technology Take Us?”
Speaker: Daniel Kraft, MD, Physician-Scientist, Inventor, Entrepreneur, Innovator
Date and Time: February 2, 2016
Schedule:
● 6:00pm Registration, Light Dinner & Networking
● 6:30pm Brief Charter Meeting
● 7:00pm Dr. Kraft’s Presentation
Location: WSGR, 650 Page Mill Rd, Palo Alto, CA
Reduced Introductory Rate:
● $10.00 Advanced registration (by Jan. 30, 2016)
● $15.00 At door, if space available
(cash or check payment only)
Reserve your spot today. Space is limited.
http://bmes.org/sfbayarea
Event Description
What is BMES? The Biomedical Engineering Society (BMES) is the professional society for
biomedical engineering and bioengineering. Founded in early 1968, the Society now boasts
nearly 6,500 members and is growing, rapidly.
Our Group's Mission is as follows: To create a biomedical industry community in the San Francisco Bay Area that provides: * Mentoring for young professionals and newcomers to industry, * Networking, * Continuing Education (e.g., technology, clinical, professional development, industry
trends, funding, regulatory, communication, interviewing), * Promotion of the Industry in the region.
16
More Information: For more information about joining our Industry Networking Group,
contact Denise Forkey, Cofounder and President, (650) 799-9258 or
Speaker Bio
Daniel Kraft is a Stanford and Harvard trained physician-scientist, inventor, entrepreneur,
and innovator. With over 20 years of experience in clinical practice, biomedical research and
healthcare innovation, Kraft has chaired the Medicine Track for Singularity University since
SU’s inception, and founded and is Executive Director of Exponential Medicine, a program
that explores convergent, rapidly developing technologies and their potential in biomedicine
and healthcare. Following undergraduate degrees from Brown University and medical school
at Stanford, Daniel was board certified in both Internal Medicine & Pediatrics after
completing a Harvard residency at the Massachusetts General Hospital & Boston Children's
Hospital, and fellowships in hematology, oncology and bone marrow transplantation at
Stanford. He has multiple patents on medical device, immunology and stem cell related
research through faculty positions with Stanford University School of Medicine and as clinical
faculty for the pediatric bone marrow transplantation service at University of California, San
Francisco.
*********************************************************************
Seminars at Stanford, Tuesday, Mid Day, Feb. 9, 2016
Topic: “Novel Technologies to Investigate the Stem Cell Niche”
Date and Time: Tuesday Feb. 9, 2016, 12:00 pm
Location: Pre-Seminars In Clark Center Room S361; Seminars In Clark Center Room S360
Event Details:
Small Lunch Served At 12:00��; Lectures Begin At12:15��
Pre-Seminars In Clark Center Room S361; Seminars In Clark Center Room S360
February 9, 2016
Pre-Seminar Speaker: Michael Lin, Departments of Pediatrics and Bioengineering
February 11, 2016
Seminar Speaker: David Schaffer, UC Berkeley
Novel Technologies to Investigate the Stem Cell Niche
**********************************************************************
Bio2Device Group, Tuesday Evening, Feb. 9, 2016
Topic: “Smarticles: A New Class of Molecular Diagnostic”
Speaker: Diego Rey, PhD , Co-Founder & Head of Research, GeneWEAVE
Date and Time: Tuesday, Feb. 9, 2016, 6:00 pm
Location: Wilson Sonsini Goodrich & Rosati- 650 Page Mill Road, Palo Alto, CA
Cost:
$6 - Students/In-transition - Members only
$11 - Early-bird Registration - Members only
$20 - Late Registration and Non-Members
$25 - Walk-ins
Register at www.bio2DeviceGroup.org
Topic Description
Multi-drug resistant organisms (MDROs) threaten modern medicine’s progress by making
common infections fatal and dramatically increasing the risk of complications for many
medical procedures such as surgery, transplants, and chemotherapy. To solve this problem
a global call has been issued to develop new diagnostics that detect MDROs and measure
antibiotic effectiveness fast enough to make time-critical clinical decisions. GeneWEAVE is
using Smarticles(TM) technology to develop fast, simple, and smart diagnostics to aid
17
healthcare providers in the fight against drug-resistant bacteria by enabling impactful
surveillance programs, early therapy guidance, and successful antibiotic stewardship. This
talk describes the Smarticles technology and tells the story behind GeneWEAVE.
Speaker Bio
Diego Rey co-founded GeneWEAVE in 2010 during his PhD studies at Cornell University.
GeneWEAVE went on to commercialize a platform technology that enables the development
of in vitro diagnostics for detecting bacteria and their antimicrobial susceptibility without the
need for sample preparation. From 2010-2015 Diego served at GeneWEAVE's Chief
Technology Officer during which time the company raised $25MM in venture capital
investment and grew to 50 employees. In August 2015, Roche acquired GeneWEAVE for up
to $425MM. Diego currently serves as the Head of Research for GeneWEAVE, a division of
Roche Molecular Systems, Inc. where he continues to develop simple to use and cost
effective diagnostics with the goal of reducing infections caused by multi drug resistant
organisms worldwide.
*********************************************************************
ACRP, Thursday Afternoon, Feb. 11, 2016
Event: Mark Your Calendars for the ACRP Virtual Career Fair
Date and Time: Thursday, February 11, 2016 from 9:00 am – 1:00 pm PT (12:00 pm –
4:00 pm EST )
Details and registration at https://app.brazenconnect.com/events/acrp-career-
fair#!eventLanding;eventCode=acrp-career-fair
The ACRP Virtual Career Fair is an excellent resource for clinical research professionals,
like yourself, to connect with the nation's top employers. Create or Update your Job
Seeker Profile NOW and don't forget to flag your resume as a participant in the Virtual
Career Fair!
How the event works:
Discover potential career opportunities, have your resume reviewed, conduct
interviews via online chat and follow-up with recruiters and employers that
interest you
Scout open positions more confidentially than at an onsite career fair
Connect with top clinical research employers regarding their current and future
hiring needs
Click here to ensure your professional profile is up-to-date
***********************************************************************
JLABS, Thursday MidDay, Feb. 11, 2016
Topic: “Lessons in Herding Cats – Business Development Basics for Life Science
Companies”
Speaker: Lesley Stolz, Ph.D. | Sr. Director, Transactions, Johnson & Johnson Innovation,
California
Date and Time: Thursday, February 11, 2016 from 10:45 AM to 1:00 PM (PST)
Agenda:
10:45 AM | Registration Opens
11:00 AM | Presentation
12:00 PM | Q&A
18
12:15 PM | Lunch and Networking
1:00 PM | Program Close
Location: Johnson & Johnson Innovation, JLABS, 329 Oyster Point Blvd., 3rd Floor, South
San Francisco, CA
Fees:
$35 | General Public
$20 | Student/Academic
$45 | Onsite
Register at http://www.eventbrite.com/e/lessons-in-herding-cats-business-development-
basics-for-life-science-companies-tickets-19858437120
Topic Description
The business development professional's purpose is to optimize optionality and long term
value at each stage of a company's life. As a company grows and gains traction, it's easy to
get enticed and overwhelmed by the numerous opportunities that arise. How do you
determine the direction that will add the most value to your company? How do you avoid
the constant pursuit of "shiny objects?" How do you know when it's the right time for a
strategic partnership?
In this workshop, you'll learn fundamental business development skills to help you
successfully evaluate and manage strategic alliances and other potential growth
opportunities.
Topics will include:
Strategic alliance process management
Concepts in valuation
Importance of IP and IP diligence
Communication and negotiation skills
Basic components of a contract
This workshop is geared towards business development professionals and management
teams of life science startups.
Speaker Bio
Lesley has been working in corporate and business development roles for the last 17 years
for companies that are both technology platform and therapeutics focused. Her most recent
executive positions have been with BioTime, a publicly traded stem cell technology and
therapeutic company, and Sutro Biopharma, a platform technology company working in cell-
free protein synthesis. Prior to Sutro, Lesley served in BD positions for a number of biotech
companies in the U.S. and Europe. Lesley received her Ph.D. in chemistry, and conducted
postdoctoral research at Harvard Medical School's Department of Biochemistry and
Molecular Pharmacology.
*****************************************************************
GGPF, Thursday Evening, Feb. 11, 2016
Topic: “Hemoperfusion with Polymeric Adsorbents in the Treatment of Drug-Resistant
Bloodstream Infections”
Speaker: Bob Ward is president of ExThera Medical
19
Date and Time: Thursday, Feb 11, 6:00 pm
6 PM social hour
7 PM dinner
8 PM lecture
Location: Michael's Restaurant at Shoreline Park, 2960 N. Shoreline Park, Mountain View,
CA 94043
Cost:
Employed/postdoc Student/unemployed/retired
Early Registration $30 $15
Registration $35 $20
Walk-in (not guaranteed) $40 $25
Lecture-only is free.
Deadline for registration:
11:59PM, Wednesday, February 3 for early registration discount.
5PM, Wednesday, February 10 for regular registration.
Registration: http://ggpf.org
Topic Description
ExThera Medical Corporation of Martinez, CA has developed the Seraph® Microbind® Affinity
Blood Filter (Seraph). Seraph is a broad-spectrum biomimetic hemoperfusion device that
removes (drug-resistant) pathogens, toxins and pro-inflammatory cytokines from whole
blood. It is designed to reduce the intensity and duration of bacterial and viral infections in
the prevention and treatment of sepsis, a major cause of death all over the world. Methods
of polymer surface modification and characterization we previously applied in the
development of blood and tissue-contacting medical devices were useful in the creation of
Seraph. Synthetic methods that maximize surface concentration of macromolecular ligands
while avoiding stearic hindrance were needed for the successful creation of a non-porous,
antithrombogenic adsorption media that mimics the binding sites used by pathogens when
they invade the human body. Seraph is currently undergoing clinical trials in Europe.
Preclinical testing of a related device, Seraph 200, was performed by Battelle Columbus
within the DARPA Dialysis-like Therapy (DLT) Program where it demonstrated excellent
safety and efficacy in the removal of methicillin resistant Staph. aureus (MRSA).
Speaker Bio
Bob Ward is president of ExThera Medical in Martinez, and founder of Berkeley-based
Polymer Technology Group (PTG), now DSM Biomedical. Bob is a chemical engineer and
polymer scientist with 44 years of experience in the development and manufacturing of
medical devices, and polymeric biomaterials for critical applications. Novel biomaterials and
components developed and manufactured under his direction have been used in dozens of
devices and prosthetic implants including artificial hearts, vascular grafts, stents,
pacemakers, orthopedic implants and contact lenses. ExThera, his fourth start-up venture,
has developed Seraph, a dialysis-like sorbent hemoperfusion device that safely removes
pathogens and toxins from blood in the treatment of drug-resistant bacteremia and
viremia. European clinical trials are currently underway.
************************************************************** HBA, Thursday Afternoon, Feb. 11, 2016
Topic: “Thriving in the 21st Century: How to Build Connected Networks”
20
Speakers: Sheila Babnis, Innovator in residence, Future State/President Insights & Impacts
and Ayelet Baron, Futurist, chief instigator, speaker, CreatingIs LLC
Date and Time: Thu, Feb 11, 2016, 4:00 PM - 7:00 PM
Agenda
4:00 - 4:15 PM Registration and networking
4:15 - 4:30 PM Welcome/BioMarin and HBA introduction
4:30 - 5:30 PM Program and table top discussion
5:30 - 5:45 PM Closing, evaluation, feedback and adjourn
5:45 - 7:00 PM Post program networking Location: BioMarin Pharmaceutical Inc., 770 Lindaro St, San Rafael, CA, 94901
Member rate:
$30 until February 4, 2016
$40 after February 4, 2016
Nonmember rate:
$45 until February 4, 2016
$55 after February 4, 2016
BioMarin employee rate:
$20 until February 4, 2016
$30 after February 4, 2016
Registration information
Event is open to: HBA members and nonmembers
Online registration deadline: February 5, 2016
Onsite (walk-in) registration: Is allowed
Space is limited to 75 registrants
Understand the essence of what it means to build your network and do real work in the 21st
century.
Register at https://my.hbanet.org/MyHBA/EventDetails.aspx?MeetingID=03F0FF27-E3B3-
E511-990B-0050569C00C5
Event description
Life is all about stories. The stories we tell ourselves and the stories we tell others. As
people, we connect with our communities and in the workplace at a human level where trust
and relationships are key to our ability to get people to not only be interested in our story
but also find ways to co-create with us in a meaningful way. We are built to form
attachments and business is all about relationships and we need to go beyond treating it
like a transaction.
A connected network knows no boundaries as it enables people internally and externally to
connect around purpose and common needs and interests. It surpasses organizational
hierarchies to connect people to each other and to ideas. In the 21st century, leaders
moved from seeing a world of scarcity where they needed to compete to one of abundance
where they can create new markets. Possibilities and opportunities are available to those
who understand that the world is open and that social media is just a bunch of tools that
help us reach people in more direct ways. They understand how to use video, for example,
as a strategic tool to build thriving relationships and ultimately, partnerships anywhere in
the world. These leaders know how to arm their business with the most valuable
technologies to reach their goals. They never lead with technology.
The future of work is already here as we live in an open and connected world where it is
easier to connect and have random collisions with people from around the world. We have
co-working spaces, co-creation, co-living spaces, open source and the growing freelance
economy.
The key to the 21st century is the ability of leaders to create space and bring together the
right people at the right time to focus on their top opportunities. In this session, you will
21
become increasingly aware of why connected networks and trusted communities are key to
your future success in leading in today’s world.
Learning objectives
1. Why are connected networks and communities key to your success
2. The seven steps to building your connected network, internally and externally
3. How to work out loud and build lifelong communities
Special instructions: Please bring a government issued ID for check-in. Please park in the
788 Lincoln Avenue garage. There will be a security officer at the entrance to allow each
non-BioMarin attendee in. Employees have a badge to scan in.
******************************************************************* JLABS, Thursday, Feb. 26, 2016
Topic: “Meet with….Sofinnova Ventures”
Speaker: Mike PowellSofinnova Ventures Participating Representative
Date and Time: Thursday, Feb. 26, 2016; 10:30 am to 1:00 pm
Agenda:
10:30am | Registration Opens and Networking
11:00am | Presentation and Q&A
11:45am | Networking Lunch
1:00-5:00pm | One-on-one Meetings*
*Companies must have applied for a one-on-one meeting ahead of time and be
approved. The application period ends on January 25th, 2016.
Location: Johnson & Johnson Innovation, JLABS, 329 Oyster Point Blvd - 3rd Floor,
South San Francisco, California
Fees:
Presentation & Lunch
$25 | General Public
$35 | General Public Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of
one-on-one meeting status. Registration to attend the presentation, Q&A, and lunch
will remain open until February 24th, 2016 (or sold out).
One-on-One Meeting
FREE | Application
FREE | Accepted Companies
Companies must have applied for a one-on-one meeting ahead of time. The one-on-
one application period ends on January 25th, 2016. Your application will be reviewed
and you will be notified of acceptance by February 11th, 2016. Acceptance of a one-
on-one meeting is not guaranteed as all applications must be approved.
Register at http://www.eventbrite.com/e/meet-with-sofinnova-ventures-tickets-
18715680103?aff=blast
Topic Description
Are you Sofinnova material? Sofinnova Ventures, a leader in funding for life sciences
companies, is visiting Johnson & Johnson Innovation, JLABS. With $2 billion under
management and a recent $500 million fund, Sofinnova is looking to invest in life
science innovators. Focus areas include clinical drug development and drug
discovery.
Since 1974, Sofinnova has partnered with entrepreneurs to secure initial funding,
build successful management teams, form impactful corporate alliances, win key
customers, and navigate acquisitions and IPOs. Sofinnova applies capital and
22
expertise to guide start-up companies to successful exits. Recent exits include Labrys
Biologics, Tesaro, and Spark.
Representatives from Sofinnova will be in attendance to give an overview
presentation about the company's key areas of interest and best practices when
seeking startup funds. Following the presentation, don't miss this opportunity to
introduce yourself to Mike Powell, General Partner, during the networking lunch. And
finally, for those companies who apply online and are approved, one-on-one meetings
with Sofinnova will provide a forum to discuss your company.
Speaker Bio
Mike Powell, Ph.D. | General Partner, Sofinnova Ventures
Mike joined Sofinnova in 1997, and SVP IX ($510M) is his sixth Sofinnova fund. He
has 32 years of experience, including 15 years of R&D before venture. Mike has been
involved in more than 50 clinical programs, and is the author of 90 publications and
books, including a 1,000-page treatise on vaccine design. He was the initial venture
investor of: Actelion (ATLN), Intermune (ITMN), Orexigen (OREX), Seattle Genetics
(SGEN), Threshold (THLD), and Trius (TSRX) and other public and private companies
such as Intellikine (sold to Millennium-Takeda), Mirna and Labrys Biologics (sold to
Teva). Mike was the first person in the biotech industry to be honored by the
American Association of Pharmaceutical Scientists as an AAPS Fellow. He has also
served on the journal editorial boards of Journal of Pharmaceutical Sciences and the
Journal of Controlled Release. He has been the Board President of the AIDS Vaccine
Advocacy Coalition, as well as advisor to the Institute for One World Health, IAVI,
and the Bill and Melinda Gates Foundation. Mike is also Adjunct Associate Professor in
the Department of Pharmaceutical Chemistry at the University of Kansas, one of the
top US pharmacy schools. Before joining Sofinnova, he was group leader of drug
delivery at Genentech. During his tenure there, he and colleagues spun off VaxGen,
an AIDS vaccine company. Prior to Genentech, he helped start Cytel as the Director
of Product Development. Before this he was Senior Scientist and Project Team Leader
at Syntex Research. Mike received his PhD in Chemistry from the University of
Toronto and carried out postdoctoral studies in bio-organic chemistry at the
University of California as a National Science and Engineering Research Council
Scholar. Mike and his wife Tana live in San Francisco, and they enjoy flying, skiing,
diving and flyfishing.
Connect with Mike: Connect on LinkedIn
*****************************************************************
PBSS, Monday, Feb. 29, 2016
Workshop: Advanced LC/MS Practices
Speakers: Jack Henion, Ph.D. Emeritus Professor of Analytical Toxicology, Cornell University
Date: Monday, February 29, 2016, 8:45-17:00
Location: SF Bay Area: Foster City Crowne Plaza
Registration fee (US$): Regular: $195; For unemployed & students: $30; For major-sponsor
rep (incl lunch): $0; For vendor-show rep: $35; For others, details available upon online
login.
Registration: http://www.PBSS.org
Further Information:
Registration deadline: 2/26/2016 (it will close sooner if the seating cap is reached)
About the Topic
Course Objective:
23
Learn effective LC/MS techniques for analyzing complex samples and characterizing organic
compounds
Who Should Attend:
Experienced LC/MS researchers and practitioners, or others involved in identifying or
measuring organic compounds in real-world samples including drugs and metabolites within
or for the pharmaceutical industry, and who work with HPLC and MS techniques. Prior HPLC
and/or LC/MS experience and understanding is assumed.
Key Topics You'll Learn About:
Principles and preferred practices for APCI LC/MS
Fundamentals and practices for optimal electrospray ionization
Principles of multiple charging in electrospray mass spectra of biomolecules
Strategies for characterizing small molecules contained in biological samples via
electrospray LC/MS and LC/MS/MS.
Sample preparation optimized for LC/MS and LC/MS/MS analyses
Initial strategies for interpreting collision-induced dissociation (CID) mass spectra of
small pharmaceutical molecules.
About the Speakers
Jack Henion is Professor Emeritus of Toxicology at Cornell University in the Analytical
Toxicology.. He is also a co-founder, Chairman, and CSO of Advion BioSciences, Inc.,
located in Ithaca, New York. Prof. Henion’s work in LC/MS relates to the analysis of real-
world samples common to pharmaceutical, environmental, and biochemical problems. The
instructor has published extensively in the areas of conventional capillary GC/MS as well as
LC/MS, SFC/MS, IC/MS, and CE/MS using atmospheric pressure ionization (API)
technologies with quadrupole, ion trap, FTMS, and time-of-flight mass spectrometers.
******************************************************************
Stanford, Thursday Mid Day, March 10, 2016
Topic: “Discerning Rare Disease Biomarkers By Micro- And Nanotechnologies”
Date And Time: Thurday, March 10, 2016, Noon
Pre-Seminars In Clark Center Room S361; Seminars In Clark Center Room S360
Small Lunch Served At 12:00��; Lectures Begin At12:15��
Pre-Seminars In Clark Center Room S361; Seminars In Clark Center Room S360
March 8, 2016
Pre-Seminar Speaker: Joe Liao, Department Of Urology
March 10, 2016
Seminar Speaker: Jeff Tza-Huei Wang, Johns Hopkins University
Discerning Rare Disease Biomarkers By Micro- And Nanotechnologies
***************************************************************
GGPF, Friday Evening, March 11, 2016
Topic: Designing Simple Polymers with Protein-like Activity: Advanced materials and new
therapies
Speaker: Gregory N. Tew, Professor in the Polymer Science and Engineering Department at
the University of Massachusetts, Amherst
Date and Time: Friday, March 11
6 PM social hour
7 PM dinner
8 PM lecture
24
Location: Michael's Restaurant at Shoreline Park, 2960 N. Shoreline Park, Mountain View,
CA 94043
Cost:
Employed/postdoc Student/unemployed/retired
Early Registration $30 $15
Registration $35 $20
Walk-in (not guaranteed) $40 $25
Lecture-only is free.
Deadline for registration:
11:59PM, Thursday, March 3 for early registration discount.
5PM, Thursday, March 10 for regular registration
Registration: http://ggpf.org
Topic Description
Our primary research aim is to create new materials using a combination of principles,
many of which are inspired by biology. In addition, the design of simple molecules that
mimic the complex structures and functions of biology is at the heart of our work. In this
presentation, we will illustrate some of these principles including novel networks with high
resilience and new delivery agents inspired by protein transduction domains (PTDs).
Coupling high efficiency click chemistry with telechelic polymer design generates new phase
separated networks that are highly elastic and have bicontinuous morphologies over a very
wide compositional range. PTD designs rely on synthetic approaches that easily allow
doubling the density of guanidine functional groups, which increases the transduction
efficiency of the sequences. Cellular uptake studies on three different cell lines (HEK 293T,
CHO, and Jurkat T cells) confirm that these synthetic analogs are highly efficient novel
protein transduction domain mimics (PTDMs), that are more effective than TAT49-57 and
nonaarginine (R9) and also highlights the usefulness of polymer chemistry at the chemistry-
biology interface.
Speaker Bio
Gregory N. Tew, Professor in the Polymer Science and Engineering Department at the
University of Massachusetts, Amherst, has more than a decade of experience transitioning
bio-inspired design concepts to practice.
He received a B.S. in Chemistry from North Carolina State University in 1995 performing
undergraduate research with Prof. D. A. Shultz and interning at Burroughs-Wellcome
Pharmaceutical. In 2000, he earned his Ph.D. from the University of Illinois-Urbana under
Prof. Samuel Stupp in Materials Science after which he joined the Faculty at the Polymer
Science and Engineering Department at the University of Massachusetts, Amherst. Before
starting there, he spent one year in William DeGrado's laboratory at the University of
Pennsylvania Medical School.
His current research interests include bioinspired and biomimetic macromolecules,
molecular self organization, nano-medicine, and materials-immunology. Greg received
every young investigator award offered by the Federal Government including the
Presidential Early Career Award for Scientists and Engineers (PECASE) which is the highest
honor recognized by Federal Funding Agencies for young faculty and presented by the White
House. He was elected as a member of the Defense Science Study Group, founding
member of the ACS Polymer Chemistry Division Fellows program, and served as board chair
of the ACS Division of Polymer Chemistry. More recently he has elected fellow of the ACS
25
and AIMBE. He has published over 150 peer-reviewed papers and serves as chair of the
SAB for PCCL, Polymer Competence Center Leoben, Austria. Greg remains interested in
technology transfer activities and mentorship. He was a scientific and original co-founder of
PolyMedix; a clinical-stage biotechnology company which has raised over $150M as well as
founding mentor of Future Faculty Workshop: Diverse Leaders of Tomorrow.
*********************************************************************************************************** PBSS Workshop, Monday – Friday, March 14-18, 2016
Workshop: “Clinical Trials Essentials: An Intensive One-Week Course (Register for full week or 4-hr sessions)”
Speakers: Edward Rozhon, Mike Huston, Pete Shabe, Savita Sinha, Clarisa Tate, Narinder Singh, Frances Ann McKenney Date and Time:: Monday, March 14, 2016, 12:30-17:00 Registration fee (US$): (USD$)One-week full course: $1865; Mon AM: Drug Development Process: $250; Mon PM: Science of Clinical Trials Design: $250; Tue AM: Clinical Data Management: $250; Tue PM: Applied Statistics in Clinical Trials; Study Site Perspective: $250; Wed AM: Monitoring Clinical Trials: $250; Wed PM: Medical Devices, An Overview: $250; Thur AM: GCP & ICH Investigator & Clinical Research Site: $250; Thur PM: Clinical QA/Compliance Audits and the FDA: $250; Good Manufacturing Practices and regulatory trends: $250; Fri PM: Global Clinical Trials Perspective; Business of Clinical Research: $250; Location: SF Bay Area: 2505 Augustine Dr, Santa Clara (UCSC-Extension in Silicon Valley) Registration: http://www.PBSS.org Registration deadline:3/12/2016 (it will close sooner if the seating cap is reached)
About the Topic
Clinical Trials Essentials: An Intensive One-Week Course
A joint course between UCSC Extension Silicon Valley and Pharmaceutical & BioScience Society -- San Francisco Bay
March 14-18, 2016
(Register for the full-week or any half-day sessions) Monday March 14, 2016 – 8:30 am—12:30 pm
Drug Development Process 4 hours – Edward Rozhon
Major players in drug development
Assay development and discovery of new medical entities
Non clinical and clinical development of new drugs
History and regulatory oversight of FDA
Structure of Phase I, II, & III clinical trials
FDA review of New Drug Application.
Monday March 14, 2016 – 1:30 pm—5:30 pm
Science of Clinical Trials Design 4 hours – Mike Huston
Phases of drug development
Objectives of clinical studies
Basic clinical trials designs
Underlying science for clinical trials designs.
Tuesday March 15, 2016 – 8:30 am—12:30 pm
Clinical Data Management 4 hours – Speaker TBA
26
Key data management activities for study startup, conduct, and closeout
Regulations applicable to data management activities
Clinical data management systems and electronic data capture (EDC)
Working with contract research organizations (CROs) for data management.
Tuesday March 15, 2016 – 1:30 pm—3:30 pm
Applied Statistics in Clinical Trials 2 hours – Pete Shabe
The role statistics plays in clinical research
Basic data summarization techniques
Estimation and Hypothesis Testing Introduction
Estimation and Confidence Intervals
Statistical Hypothesis Testing.
Tuesday March 15, 2016 – 3:45—5:30 pm
Study Site Perspective 2 hours – Speaker TBA
Translational research in an academic center: fundamental strengths and
weaknesses
Research Process and Operations management as the success of a trial
Essential conversations between academia, biomedical and pharmaceutical
companies, venture capitalists and consultants
Data Integrity and well-supported metrics (Case Studies).
Wednesday March 16, 2016 – 8:30 am—12:30 pm
Monitoring Clinical Trials 4 hours – Savita O. Sinha
Review the basic regulatory requirements of monitoring a clinical research study
Describe the tasks that should be performed before, during, and after a monitoring
visit
Learn how to track all key parameters involved in monitoring a site
Know how to complete visit reports and follow-up on action items after each site
visit.
Wednesday March 16, 2016 – 1:30 pm—5:30 pm
Medical Devices, An Overview 4 hours – Clarisa Tate
What is a medical device, an general overview of regulations
Medical devices regulatory pathways: 510(k), PMA, and HDE
Medical device clinical trials: Focus on Investigational Device Exemptions
Post-market surveillance: Focus on 522, complaints, and recalls
Globalization and changing regulatory environment.
Thursday March 17, 2016 – 8:30 am—12:30 pm
GCP & ICH Investigator & Clinical Research Site 4 hours – Narinder Singh
Historical and legislative roads to Good Clinical Practices (GCP)
Principles of GCP and the research-care conflict
Role of various stakeholders in Clinical Trials
Elements of informed consent.
Thursday March 17, 2016 – 1:30 pm—5:30 pm
Clinical QA/Compliance Audits and the FDA 4 hours – Frances Ann McKenney
Qualifications needed for GXP auditors and FDA Inspectors
Objectives of sponsor audits and regulatory inspections
Similarities and differences between sponsor audits and regulatory inspections
General approach to hosting an audit or inspection
Types of findings that cause concern for auditors or inspectors.
27
Friday March 18, 2016 – 8:30 am—12:30 pm
Good Manufacturing Practices and regulatory trends 4 hours – Narinder Singh
Good Manufacturing Practices (GMP) for drugs
GMP for biologics and related products, including Good Tissue Practices
Considerations for Quality Systems.
Friday March 18, 2016 – 1:30 pm—2:30 pm
Global Clinical Trials Perspective 1 hour -- Narinder Singh
Trends in global clinical trials.
Role of FDA and local regulatory culture.
Friday March 18, 2016 – 2:45 pm—5:30 pm
Business of Clinical Research 2 hours – Mike Huston
The Market Players – Pharma, Biotech, Contract Research Organizations (CROs)
Cost of Doing Business – Cost of conducting clinical research
Outsourcing and CROs – It costs money to make money
Innovative Ways to Reduce Cost – Business Strategies and Process Innovations.
***********************************************************************************************************
EPPICON, Saturday, March 26, 2016
Event: EPPICon 2016
March 26, 2016, 8:00pm
Location: Crowne Plaza Hotel San Francisco Airport 1177 Airport Blvd, Burlingame, CA
94010
The Tenth Annual flagship event from EPPIC Global Network, a non-profit professional
organization in the San Francisco Bay Area with a mission to provide a platform for fostering
entrepreneurship, professional networking and mentoring in the life sciences and healthcare
space.
Save The Date: Saturday, March 26, 2016
Who Should Attend
Entrepreneurs, Innovators, Researchers, Investors and Professionals (including Service Providers) from Pharma, Biotech, Diagnostics, Devices and Digital Health
Past Speakers at EPPICon
Vivek Wadhwa, Kim Bush, Ann Lee, Corey Goodman, Hal Barron, Norman Winarsky, Kiran
Mazumdar-Shaw, Kevin Davies and many more…
Stay tuned - we will be back with more!
Visit us at www.eppicglobal.org
Chitra Sharma (Convenor, EPPICon 2016 & EPPIC President Elect)
Anjali Pandey & Amita Goel (Co-Chairs, EPPICon 2016 & EPPIC Charter Members)
EPPICon 2016 Organizing Committee
EPPIC GLOBAL
www.eppicglobal.org
[email protected] (408) 357-0601
28
**************************************************************
BioX Program Stanford, Thursday Mid Day, April 7, 2016
Topic: “Optical Control and Interrogation of Protein Activity Using Engineered
Photoreceptors”
Speaker: Speaker: Bianxiao Cui, Department of Chemistry
Thursday, April 7, 2016, 12:00 pm
Location:
PRE-SEMINARS IN CLARK CENTER ROOM S361; SEMINARS IN CLARK CENTER ROOM S360
SMALL LUNCH SERVED AT 12:00��; LECTURES BEGIN AT12:15��
PRE-SEMINARS IN CLARK CENTER ROOM S361; SEMINARS IN CLARK CENTER ROOM S360
*************************************************************
Bio-X Frontiers, Tuesday, April 26, 2016
Topic: “Integration Of Systems Biology, Tissue Engineering, And Microdevices For Drug
Development”
Pre-Seminar Speaker: Ovijit Chaudhuri, Department Of Mechanical Engineering
April 28, 2016
Seminar Speaker: Linda Griffith, Mit --Integration Of Systems Biology, Tissue Engineering,
And Microdevices For Drug Development
Date And Time: Tuesday, April 26, 2016, Noon
Location:
Pre-Seminars In Clark Center Room S361; Seminars In Clark Center Room S360
Small Lunch Served At 12:00��; Lectures Begin At12:15��
Pre-Seminars In Clark Center Room S361; Seminars In Clark Center Room S360
********************************************************
Bio-X, Saturday, May 7, 2016
In vitro Vascularized Constructs as Models of Metastatic Cancer
Date and Time: Saturday, May 7, 2016, noon
Location:
PRE-SEMINARS IN CLARK CENTER ROOM S361; SEMINARS IN CLARK CENTER ROOM S360
SMALL LUNCH SERVED AT 12:00��; LECTURES BEGIN AT12:15��
PRE-SEMINARS IN CLARK CENTER ROOM S361; SEMINARS IN CLARK CENTER ROOM S360
Pre-Seminar Speaker: Alexander Dunn, Department of Chemical Engineering
May 19, 2016
Seminar Speaker: Roger Kamm, MIT In vitro Vascularized Constructs as Models of Metastatic Cancer
***************************** BIO International Conference, June 6 – 9, 2016
29
Dates: June 6 – 9, 2016
Location: Moscone Convention Center, North, South and West Halls
Fees: Convention Access - $1,200, Members and 1,450, Non Members before April 16;
$1,400, Members and $1,750 for nonmembers after April 16 (see other package pricing at
http://convention.bio.org/register/)
*****************************************************************
BIO Career Fair, Thursday Afternoon, June 9, 2016
Event: BIO Career Fair
Date and Time: Thursday, June 9, 2016, 2:00 – 7:00 pm
Cost: Free
Details and registration at http://convention.bio.org/careerfair-jobseekers/
BIO is proud to announce the 2016 BIO Career Fair, Thursday June 9 from 2:00 - 7:00 pm.
As an extension of BIO’s online job board—Bio Jobs—the Career Fair will provide an opportunity for meeting participants and top employers to discuss career opportunities..
The BIO Career Fair (is free) and will allow you access to many of the world’s leading life
science companies. A minimum of a 4-year life science degree OR a community college
biotech degree is recommended and military veterans are encouraged to apply. Details at
More information coming soon!
*********************************************************************
HPLC, Sunday, June 19, 2016
Topic: “HPLC 2016 - 44th International Symposium and Exhibit on High Performance Liquid
Phase Separations and Related Techniques”
Date and Time: Sunday, June 19, 2016 , 8:30 am
Location: Mariott San Francisco Marquis
The goal of HPLC 2016 is to bring together scientists who use and develop
HPLC, capillary electrophoresis, supercritical fluidic chromatography, microfluidics, and mass
spectrometry to exchange ideas, best practices, and
latest developments. The conference program is guided by emerging trends in
separations technology and their impact on science and society.
THREE SESSION TRACKS AT HPLC 2016:
Technology: Better, Faster, Quantitative Separations
Interface to MS: Improving Information Content
BioAnalysis and Applications: Impacting Science and Society
Topics include column and stationary phase technology, interface to mass spectrometry,
microfluidic systems, capillary electrophoresis, LCxLC, QA&QC methods, QbD in separations,
and application to real world problems. A special emphasis in applications will be on
bioanalysis including:
pharmaceuticals, antibody-drug conjugates, antibody characterization, biotechnology,
proteins and proteomics, glycomics, metabolomics and lipidomics, food and nutrition, well-
characterized biologicals, biofuels, environment, and toxicology.
Also Featuring:
Tutorials, Short Courses, User Group Meetings, and Lunch Technical Sessions
For more information, visit: www.hplc2016.org
http://www.hplc2016.org/index.html
30
Type of Registration: Fees are posted under the "Online Registration" tab located at
www.HPLC2016.org.
Payment must be made by check or credit card payable in US Dollars and drawn on a US bank (no bank wire transfers).
Registration is not accepted or acknowledged until payment is received.
By submitting this registration, you authorize the HPLC 2016 meeting to share your
information with attendees, etc.
Student Registrants: In order for the student rate to be accepted, must submit proof of
current full-time graduate or undergraduate, not postdoctoral, status at an academic
institution by providing both a copy of your Student I.D and a letter on university stationery
from your department chair along with the department chair contact details and email.
Email the letter and copy of the Student ID to [email protected].
All Oral and Poster Presenters: In order to present, the presenting author of each lecture
and poster must be registered as a conference attendee (not booth staff) and must
complete the registration process by paying online by April 18 to confirm intent to attend
and present at the meeting. If fees are not paid, submissions from that author will be
removed from the program.
Refund Policy: A processing fee of 20% will be collected on cancellations on or before April
1, 2016, after which the fees are non-refundable. Registration is transferable; must contact
Symposium Manager by no later than one week prior to the conference to transfer and
receive confirmation of the transfer of the registration ([email protected] or telephone 301-668-6001).
HPLC 2016 Symposium/Exhibit Manager
Ms. Janet Cunningham
Barr Enterprises
www.LinkedIn.com/in/BarrEnterprises
phone 301-668-6001
[email protected] www.HPLC2016.org
***********************************************************
Bio2Device Group, Tuesday Evening, August 9, 2016
Topic: TBA
Speaker: Dr. Allison Dupuy, Partner, Simon-Kucher
Date and Time: Tuesday, Aug. 9, 2016, 6:00 pm
Date and Time: Tuesday, Oct. 13, 2015, 6:00pm
Location: Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto CA
Cost:
$6 - Students/In-transition - Members only
$11 - Early-bird Registration - Members only
$20 - Late Registration and Non-Members
$25 - Walk-ins (as space permits)
31
Register at www.Bio2DeviceGroup.org
Speaker Bio
Dr. Allison Dupuy is a Partner in the Life Sciences division of Simon-Kucher & Partners in
San Francisco and leads the company’s life sciences practice on the west coast of the
US. She joined the team in San Francisco in August 2012 after spending 5 years in
Simon-Kucher’s Boston office.
In her work at Simon-Kucher, she focuses on strategic pharmaceutical marketing, value-
to-customer, market entry strategies, pricing and market access strategies, innovative
pricing strategies, product lifecycle strategies, licensing and valuation, market
forecasting and value communication, including global value story development and
implementation. She is a trusted advisor of leading pharmaceutical and biotech
companies across a wide range of therapeutic areas in all major healthcare markets
across the globe.
Dr. Dupuy received her Ph.D. and M.Phil. in Molecular Biophysics and Biochemistry from
Yale University and a B.A. in Physics with honors from Wellesley College where she was
a Goldwater Scholar and a Schiff Fellow.
She is the author and coauthor of several scientific publications and has research
experience in theoretical and experimental physics, biophysics, cell biology, cancer
biology, genomics, proteomics, bioinformatics and biochemistry.